25.23
price up icon3.19%   0.78
pre-market  プレマーケット:  25.11   -0.12   -0.48%
loading
前日終値:
$24.45
開ける:
$24.96
24時間の取引高:
753.75K
Relative Volume:
1.03
時価総額:
$1.90B
収益:
$122.87M
当期純損益:
$-73.68M
株価収益率:
-25.74
EPS:
-0.9803
ネットキャッシュフロー:
$-39.27M
1週間 パフォーマンス:
+4.60%
1か月 パフォーマンス:
+9.17%
6か月 パフォーマンス:
+79.19%
1年 パフォーマンス:
+97.88%
1日の値動き範囲:
Value
$24.59
$25.58
1週間の範囲:
Value
$22.26
$25.58
52週間の値動き範囲:
Value
$9.03
$28.49

Zymeworks Inc. Stock (ZYME) Company Profile

Name
名前
Zymeworks Inc.
Name
セクター
Healthcare (1106)
Name
電話
604-678-1388
Name
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
職員
170
Name
Twitter
@ZymeworksInc
Name
次回の収益日
2026-03-02
Name
最新のSEC提出書
Name
ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ZYME
Zymeworks Inc.
25.23 1.84B 122.87M -73.68M -39.27M -0.9803
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-12 アップグレード Wells Fargo Equal Weight → Overweight
2025-12-03 開始されました Citizens JMP Mkt Outperform
2025-10-24 再開されました Wells Fargo Equal Weight
2025-10-14 アップグレード H.C. Wainwright Neutral → Buy
2025-10-10 開始されました B. Riley Securities Buy
2025-05-20 開始されました TD Cowen Buy
2024-12-16 アップグレード JP Morgan Neutral → Overweight
2024-11-07 アップグレード Leerink Partners Market Perform → Outperform
2024-11-01 ダウングレード Wells Fargo Overweight → Equal Weight
2023-03-21 再開されました Wells Fargo Overweight
2023-01-04 繰り返されました H.C. Wainwright Neutral
2022-12-20 アップグレード Jefferies Hold → Buy
2022-11-01 ダウングレード H.C. Wainwright Buy → Neutral
2022-10-21 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-10-04 再開されました Wells Fargo Overweight
2022-05-05 アップグレード Guggenheim Neutral → Buy
2022-03-15 開始されました Evercore ISI Outperform
2021-12-10 アップグレード SVB Leerink Mkt Perform → Outperform
2021-11-17 再開されました Guggenheim Neutral
2021-10-07 開始されました Jefferies Hold
2021-03-31 開始されました Credit Suisse Outperform
2021-02-25 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-02-08 再開されました H.C. Wainwright Buy
2021-01-25 ダウングレード Citigroup Buy → Neutral
2020-09-29 再開されました JP Morgan Neutral
2020-08-06 開始されました SVB Leerink Outperform
2020-01-10 開始されました Wolfe Research Outperform
2019-12-09 開始されました JP Morgan Neutral
2019-11-25 開始されました H.C. Wainwright Buy
2019-11-20 開始されました Guggenheim Buy
2019-09-30 アップグレード Raymond James Outperform → Strong Buy
2019-08-30 開始されました Stifel Buy
2019-07-18 開始されました Deutsche Bank Buy
2018-05-11 アップグレード Barclays Underweight → Equal Weight
2018-03-19 開始されました Raymond James Outperform
すべてを表示

Zymeworks Inc. (ZYME) 最新ニュース

pulisher
Mar 04, 2026

Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha

Mar 04, 2026
pulisher
Mar 03, 2026

Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga

Mar 03, 2026
pulisher
Mar 03, 2026

Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

Stifel raises Zymeworks stock price target on royalty deal value - Investing.com

Mar 03, 2026
pulisher
Mar 03, 2026

Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 03, 2026
pulisher
Mar 03, 2026

Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com India

Mar 03, 2026
pulisher
Mar 03, 2026

Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Canada

Mar 03, 2026
pulisher
Mar 03, 2026

Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus

Mar 03, 2026
pulisher
Mar 02, 2026

Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com UK

Mar 02, 2026
pulisher
Mar 02, 2026

Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget

Mar 02, 2026
pulisher
Mar 02, 2026

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz

Mar 02, 2026
pulisher
Mar 02, 2026

Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK

Mar 02, 2026
pulisher
Mar 02, 2026

Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens - AlphaStreet News

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-03-02 - Seeking Alpha

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - AOL.com

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Reports FY25 Results, Secures $250 Million Royalty Financing - Nasdaq

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Monetizes Ziihera Royalties to Boost Liquidity - TipRanks

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity - TipRanks

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks 2025 10-K: $106M Revenue, $(1.08) EPS - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc. Q4 Loss Widens - Nasdaq

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq

Mar 02, 2026
pulisher
Mar 02, 2026

Zymeworks Inc. Reports Financial Results for 2025 and Updates on Ziihera® Development and Strategic Plans - Quiver Quantitative

Mar 02, 2026
pulisher
Mar 02, 2026

$250M cancer drug royalty deal extends Zymeworks’ cash runway - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Earnings Breakdown: Zymeworks Q4 - Sahm

Mar 02, 2026
pulisher
Mar 01, 2026

Aug Levels: How sensitive is Zymeworks Inc to inflationMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn

Mar 01, 2026
pulisher
Feb 27, 2026

A Look Ahead: Zymeworks's Earnings Forecast - Benzinga

Feb 27, 2026
pulisher
Feb 27, 2026

Zymeworks Inc. (ZYME) Stock Analysis: A High Upside Prospect with Promising Biotech Innovations - DirectorsTalk Interviews

Feb 27, 2026
pulisher
Feb 20, 2026

Zymeworks Inc. (ZYME) Stock Analysis: Biotech Innovator With 56% Potential Upside - DirectorsTalk Interviews

Feb 20, 2026
pulisher
Feb 18, 2026

Does Zymeworks Inc stock have upside surprise potential2025 Market Sentiment & Accurate Intraday Trade Tips - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 17, 2026

Zymeworks (ZYME) Form 144 shows insider sell request of 31,641 shares - Stock Titan

Feb 17, 2026
pulisher
Feb 17, 2026

How Zymeworks Inc. (ZYME) Affects Rotational Strategy Timing - Stock Traders Daily

Feb 17, 2026
pulisher
Feb 16, 2026

How Zymeworks Inc. stock valuations compare to rivalsTrade Exit Summary & Long-Term Capital Growth Ideas - mfd.ru

Feb 16, 2026
pulisher
Feb 14, 2026

What is Zymeworks Inc.’s TAM (Total Addressable Market)Long Setup & Precise Buy Zone Identification - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Zymeworks Inc. (ZYME) Stock Analysis: A Biotech Gem With 57% Potential Upside - DirectorsTalk Interviews

Feb 14, 2026
pulisher
Feb 12, 2026

Should I average down on Zymeworks Inc. stockJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

Is Zymeworks Inc.’s ROE strong enough2025 Short Interest & Precise Trade Entry Recommendations - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

Zymeworks Sets Date for 2025 Results and Corporate Update - TipRanks

Feb 12, 2026
pulisher
Feb 12, 2026

Zymeworks Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative

Feb 12, 2026
pulisher
Feb 12, 2026

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire

Feb 12, 2026
pulisher
Feb 07, 2026

Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Feb 07, 2026
pulisher
Feb 06, 2026

Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN

Feb 06, 2026

Zymeworks Inc. (ZYME) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
大文字化:     |  ボリューム (24 時間):